Latest News

The market for Yanbu National Petrochemical Company's ( TADAWUL:2290 ) shares didn't move much after it posted weak...

The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...

Solvay stock moves after recent performance data Solvay (ENXTBR:SOLB) has come into focus after a period in which the stock showed negative returns over the past month and past 3 months, prompting closer attention to its fundamentals and profitability profile. See our latest analysis for Solvay. At a share price of €26.28, Solvay’s recent 7 day share price return of a 5.81% decline adds to a year to date share price return of a 3.88% decline, contrasting with a 42.41% three year total...

SmartCraft Group (OM:SMCRT) has posted its FY 2025 results with fourth quarter revenue of NOK 143.6 million and basic EPS of NOK 0.06. These figures are set against trailing 12 month revenue of NOK 558.9 million and EPS of NOK 0.50, which frame the year as a whole. Over recent periods the company has seen quarterly revenue move from NOK 136.1 million in Q4 2024 to NOK 143.6 million in Q4 2025, while quarterly EPS shifted from NOK 0.16 to NOK 0.06. This puts more focus on how sustainable...

Kimco Realty reported past first-quarter 2026 results showing year-over-year growth, with revenue rising to US$558.02 million and net income to US$164.9 million, while also declaring quarterly common and preferred dividends. Alongside these results, management raised full-year 2026 net income guidance per diluted share, signaling increased confidence in the company’s earnings outlook and cash flow visibility. Next, we’ll examine how Kimco’s higher full-year net income guidance influences its...

ImmunityBio (IBRX) is under close watch after an FDA warning letter on allegedly misleading promotional claims for Anktiva and a series of class action lawsuits, even as the company reports recent revenue and global approval figures. See our latest analysis for ImmunityBio. After touching a 1 day share price return of negative 7.4% following the FDA warning letter and class action headlines, ImmunityBio still sits at US$7.76 with a year to date share price return of 284.16% and a 1 year total...

EDP (ENXTLS:EDP) just wrapped up FY 2025 with fourth quarter revenue of €4.2b and basic EPS of €0.05, setting the tone for a year where trailing twelve month revenue reached €15.6b and EPS came in at €0.28. Over the past few reporting periods, revenue has ranged between €3.6b and €4.2b per quarter, while quarterly EPS moved from €0.10 in Q1 2025 to €0.07 in Q2, €0.06 in Q3 and €0.05 in Q4, against a backdrop of 43.5% earnings growth over the last year and a current net profit margin of 7.4%...

Context and recent stock performance Booking Holdings (BKNG) has drawn attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and past year. This recent stretch contrasts with the longer term, where Booking Holdings shows positive total returns over the past 3 and 5 years. As a result, some investors are reassessing how current pricing lines up with the company’s fundamentals. See our latest analysis for...

Wondering if Fox at around US$62.69 is priced for opportunity or already reflects the story? This piece walks through the key numbers to help you frame that question clearly. The stock has seen mixed recent returns, with a 1.3% decline over the last week, a 5.1% gain over the last 30 days, a 15.0% decline year to date and a 25.5% return over the last year, alongside longer term returns of 112.3% over three years and 72.6% over five years. Recent market interest has been shaped by ongoing...

Array Digital Infrastructure (AD) has reported full year 2025 results with fourth quarter revenue of US$60.3 million and basic EPS of US$0.48, alongside trailing twelve month EPS of US$1.97 on revenue of US$163.0 million and net income from ongoing operations of US$169.7 million. Over recent periods the company has seen quarterly revenue move between US$25.7 million and US$60.3 million, while basic EPS has ranged from a loss of US$1.12 per share to a profit of US$1.26 per share. This gives...

1stdibs.Com (DIBS) closed out FY 2025 with Q4 revenue of US$23.0 million and a basic EPS loss of US$0.03, while trailing 12-month revenue was US$89.6 million and EPS a loss of US$0.38. Over the past six reported quarters, revenue has moved between US$21.2 million and US$22.8 million per quarter, while basic EPS losses have ranged from US$0.15 to US$0.03. This has left investors focused on how much further margins can tighten or stabilize from here. See our full analysis for 1stdibs.Com. With...

Earnings, backlog and dividends draw fresh attention to WSP Global WSP Global (TSX:WSP) has moved back onto investor radars after reporting first quarter 2026 results that exceeded profitability expectations, reaching a record project backlog and pairing those figures with a newly affirmed quarterly dividend. See our latest analysis for WSP Global. The latest Q1 earnings beat, record backlog and affirmed dividend come after a period of weaker momentum, with a 90 day share price return of a...

Recent price moves and performance snapshot Integra LifeSciences Holdings (IART) has drawn attention after a sharp move, with the stock up about 29% over the past week and roughly 45% over the past month from its recent levels. See our latest analysis for Integra LifeSciences Holdings. That surge sits against a mixed backdrop, with a 90 day share price return of 20.43% and a 3 year total shareholder return decline of 72.66%, suggesting recent momentum is rebuilding after a tough stretch. If...

In early May 2026, Coherent Corp. reported third-quarter fiscal 2026 sales of US$1,805.64 million and net income of US$191.40 million, both up sharply from a year earlier, while also confirming strong AI data center and communications demand and a multiyear, multi‑billion‑dollar collaboration with NVIDIA. Alongside this, Coherent is rapidly expanding its 6‑inch indium phosphide wafer capacity and simplifying its capital structure, positioning its photonics business more squarely around...

If you are wondering whether American States Water at around US$76.84 is priced fairly or offering value, it helps to step back and look at what the recent share performance and fundamentals are signaling. Over the short term the stock is up 2.1% over the last week and is roughly flat over the past month with a 0.1% decline, while year to date it is up 6.3% and the 1 year return sits at a 1.8% decline. These moves come as investors continue to react to company specific developments and the...

Halozyme Therapeutics (NasdaqGS:HALO) has entered a new global collaboration with GSK to apply its ENHANZE technology to subcutaneous delivery of multiple oncology products. The agreement includes development of subcutaneous formulations for antibody drug conjugates, expanding ENHANZE into a new class of cancer therapies. The collaboration introduces additional potential royalty streams tied to future use of ENHANZE across GSK’s oncology portfolio. Halozyme Therapeutics, trading at $65.19,...

Oculis Holding secured a formal Special Protocol Assessment from the FDA for its pivotal Phase 3 PIONEER-1 trial of Privosegtor in optic neuritis. The FDA agreement confirms that the PIONEER-1 trial design is adequate to support a potential future NDA submission. In parallel, new findings from the DME AWARE study support further development of OCS-01 eye drops for diabetic macular edema. These updates arrive with NasdaqGM:OCS trading at $31.09, with the stock up 13.1% over the past week and...

RPM International (RPM) drew fresh attention after reporting third quarter fiscal 2026 earnings and sales that exceeded expectations, alongside guidance regarding sales and adjusted EBIT. See our latest analysis for RPM International. The share price has eased back recently, with a 1 month share price return of 4.84% but a 90 day share price return decline of 13.30%, while the 1 year total shareholder return decline of 6.79% contrasts with a 3 year total shareholder return of 32.76%. This...

Novartis has started construction on a new radioligand therapy manufacturing facility in Denton, Texas. The Denton site expands the company’s US network for advanced cancer treatments and is part of a broader multi year, multi billion dollar US investment plan. The project is expected to support access to personalized cancer therapies and create jobs in bioengineering and advanced manufacturing. For investors following Novartis (SWX:NOVN), the Denton build out comes as the stock trades...

InPlay Oil (TSX:IPO) has wrapped up FY 2025 with Q4 revenue of C$70.9 million and basic EPS of C$0.11, while trailing twelve month figures show total revenue of C$251.8 million and a basic EPS loss of C$0.32 alongside net income of C$7.8 million in losses. Over recent periods the company has seen quarterly revenue move from C$34.8 million in Q4 2024 to C$70.9 million in Q4 2025, with EPS shifting from C$0.15 to C$0.11. This sets up a picture where higher sales have not yet translated into...

Wondering if Tomra Systems at around kr96.0 is starting to look interesting again, or if the stock still carries more risk than reward for you? The share price has edged up about 2.4% over the last week, but that comes after declines of roughly 18.4% over 30 days, 29.7% year to date, and 32.6% over the past year. Those returns sit against a backdrop of ongoing attention on resource efficiency, recycling, and deposit return systems. Tomra Systems plays a central role in these areas globally...

Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or if the easy gains are behind it. The stock has pulled back 18.8% over the last week and 22.5% over the last month, yet it still shows a 15.7% gain year to date and a 96.6% return over the past year. These sharp moves are drawing attention back to what is already priced into Phibro Animal Health and how much of its story is reflected in the current share price. Ongoing interest...

Recent performance puts Apple Hospitality REIT in focus Apple Hospitality REIT (APLE) has drawn fresh attention after a one-month return of about 19% and a gain of roughly 14% over the past three months, prompting investors to reassess the hotel-focused REIT’s recent momentum. See our latest analysis for Apple Hospitality REIT. At a share price of $13.89, Apple Hospitality REIT’s recent 19.43% 1 month share price return and 15.17% year to date share price return contrast with a steadier 1...

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...